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Background: The role of radiation therapy (RT) in the management of gastrointestinal stromal tumors (GIST) is not
well described. Here we report our institutional experience for patients with locally advanced or metastatic GIST
treated with RT.
Methods: Between 1997 and 2012, 15 patients with 22 GISTs were treated with RT at our center. The median age
was 68 (range, 41–86). Fourteen patients had stage IV disease and 1 patient had stage IIIB disease, per the American
Joint Committee on Cancer (AJCC), 7th Edition staging. Tumors were in a variety of locations, and were most
commonly referred for palliative treatment. Eighteen of 22 tumors were symptomatic. Prior to RT, 14 of 15 patients
received systemic therapy in the form of tyrosine kinase inhibitors (TKIs) (n = 11), chemotherapy (n = 4), or both
(n = 1). TKIs were used concurrently for nine tumors (40.9%). No tumors were treated with concurrent
chemotherapy. Several fractionation schemes were used, most commonly 3 Gy × 10 (n = 8). Local progression-free
survival and overall survival were estimated using the Kaplan-Meier method. Acute toxicity was graded per
Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Results: The median follow-up was 5.1 months (range, 1.3-28.3). At the time of analysis, 12 patients have died
(80%). The estimated 6-month local progression-free survival and overall survival were 57.0% and 57.8%, respectively.
Among the 18 symptomatic tumors, at least partial palliation was achieved in 17 (94.4%), and symptoms were
completely palliated in eight (44.4%). Treatment was well tolerated, with no Grade 4 or 5 toxicities. There was no
Grade ≥3 toxicity associated with concurrent TKI use.
Conclusions: In this largest series to date of GISTs treated with RT, a high rate of palliation was achieved for
symptomatic tumors in a cohort of advanced stage, heavily pretreated patients. Treatment was well tolerated, and
concurrent use of tyrosine kinase inhibitor therapy was not associated with additional toxicity. While follow-up was
short, durable control is possible for some patients, providing evidence that GIST is not universally radioresistant
and that RT can provide an important benefit in patients with progressive or metastatic disease.
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Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal
tract, with an estimated annual incidence of 6.8 per mil-
lion in the United States [1] and 10 per million worldwide
[2]. The management of GISTs consists of surgical resec-
tion for localized and potentially resectable tumors, but* Correspondence: wua@mskcc.org
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stated.more than half of patients that undergo complete resec-
tion develop recurrence within 5 years [3] and are often
treated with systemic salvage therapy. Imatinib, a selective
inhibitor of the KIT protein tyrosine kinase, demonstrates
superior activity against most GISTs and has led to a dra-
matic improvement in progression free survival among pa-
tients with advanced or recurrent disease [4-8]. Although
initial response rates to biologically targeted agents are ex-
cellent, many patients develop resistance or metastatic dis-
ease, at which point further treatment options are limited.Ltd. This is an Open Access article distributed under the terms of the Creative
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mors is lacking. Several case reports have indicated that
radiation can reduce tumor burden and produce durable
local control in locally advanced and metastatic tumors
[9-20], but, to our knowledge, a robust analysis of its effect
in a cohort of patients has not been performed. To further
investigate the role of radiation therapy in the treatment
of GISTs, we retrospectively analyzed our institutional ex-
perience with patients that had locally advanced or meta-
static GISTs treated with radiation therapy.
Materials and methods
Patient and tumor characteristics
Between 1997 and 2012, a total of 15 patients with 22
GISTs were treated with radiation therapy for either a pri-
mary tumor or metastatic disease at our center. These
patients were retrospectively identified and placed into a
database. Patient characteristics, treatment details, and tox-
icity information were obtained through chart review. This
study was carried out as Study of Existing Data-Application
for Exemption from IRB/PB Review, and approval was
obtained for a waiver from HIPAA authorization and in-
formed consent as per 45 CFR 164.512(i)(2)(ii) and 45 CFR
46.116(d) (waiver WA0552-12).
The median age of patients was 68 years. The majority
of patients had metastatic disease at the time of their radi-
ation treatment, and one patient had stage IIIB disease ac-
cording to the American Joint Committee on Cancer
(AJCC) 7th edition staging. The most common reason
that patients were referred for radiation therapy was for
palliation of symptoms related to progressive disease (18/
22, 82%). Symptoms included pain (n = 12), pain with
weakness or numbness (n = 2), bleeding (n = 2), pain with
lower-extremity edema (n = 1), and partial bowel obstruc-
tion and constipation (n = 1). For those patients that did
not have symptomatic tumors, the indications for treat-
ment included the prevention of neurological compromise
in the spine (n = 3) and attempted preoperative cytoreduc-
tion for an unresectable pelvic tumor (n = 1).
Radiation therapy
Radiation therapy consisted of megavoltage x-rays deliv-
ered by linear accelerator. Tumors were most often
treated with 300 cGy × 10 fractions (n = 8). Other conven-
tional fractionation schemes included 180 cGy × 25 and
200 cGy × 25. Stereotactic body radiation therapy (SBRT),
defined as hypofractionation of ≥500 cGy per fraction util-
izing image guidance for delivery, was used for 9 tumors
(2400 cGy × 1, n = 2; 900 cGy × 3, n = 2; 800 cGy × 3, n = 1;
600 cGy × 5, n = 2; and 500 cGy × 5, n = 2).Three patients
were treated with a partial course of 300 cGy × 10 but did
not complete their course due to clinical deterioration
while on treatment. Conventional opposed photon fields
were used in the treatment of 13 tumors (59.1%) andIMRT was used for nine tumors (40.9%) in the abdomen,
pelvis, and paraspinal region.
Systemic therapy
Prior to radiation therapy, 14 of the 15 patients received
systemic therapy in the form of tyrosine kinase inhibitors
(TKIs) (n = 11), chemotherapy (n = 4), or both (n = 1).TKIs
that were used prior to radiation therapy included ima-
tinib for all 11 patients, sunitinib in 7 patients, sorafenib
in 5 patients, nilotinib in 1 patient and pazopanib in 1 pa-
tient. Other systemic agents used before radiation therapy
included mesna, doxorubicin, ifosfamide and dacarbazine
(MAID) and postoperative mitoxantrone (n = 1), doxo-
rubicin and dacarbazine (n = 1), doxorubicin, paclitaxel
and flavopiridol (n = 1), and doxorubicin and vinorelbine
(n = 1). Notably, all patients treated with these systemic
agents developed progressive disease.
TKIs were used concurrently (imatinib [n = 4], niloti-
nib [n = 3], sorafenib [n = 1], and sunitinib [n = 1]) with
radiation therapy for the treatment of 9 of the 22 tu-
mors, 6 of which (66.7%) were treated with SBRT, No
tumors were treated with concurrent chemotherapy.
Follow-up
Patients were assessed weekly while on treatment. There-
after, patients were seen at variable intervals by a multidis-
ciplinary disease-management team that generally included
surgeons, medical oncologists, and radiation oncologists.
The median interval between follow-up visits was 5 weeks
(range, 2–12). At each on-treatment visit and follow-up
visit, toxicity was assessed per Common Terminology
Criteria for Adverse Events (CTCAE) v4.0. Effectiveness of
palliation was assessed during on-treatment visits and at
the time of follow-up. A patient was considered to have
partial palliation if there was any appreciable improve-
ment of symptoms after beginning radiation therapy.
Complete palliation was defined as the complete reso-
lution of the presenting symptoms after the beginning
of radiation therapy.
Follow-up imaging was available for assessment in 17 of
the 22 tumors. Initial radiographic response was assessed
according to Response Evaluation Criteria in Solid Tu-
mors (RECIST). The median time to the first radiographic
assessment after radiation therapy was 2.2 months.
Local progression was defined as any clinical or radio-
graphic evidence of tumor growth. Overall survival was
defined from the date of the first radiation treatment to
the date of death from any cause. Local progression-free
survival and overall survival were estimated using the
Kaplan-Meier method.
Results
The median follow-up of the entire cohort was 5.1 months
(range, 1.4-28.3). At the time of analysis, 12 of the 15
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symptomatic at presentation and treated with palliative in-
tent, at least partial palliation was achieved in 17 tumors
(94.4%). Symptoms were completely palliated in eight
tumors (44.4%).
Partial radiographic response was seen in 35.3% (n = 6) of
tumors. Stable disease was seen in 52.9% of tumors (n = 9)
and progressive disease in 11.8% (n = 2). Among tumors
treated with SBRT with radiographic follow up (n = 8),
partial response was seen in 62.5% (n = 5), stable disease
was seen in 25.0% (n = 2), and progressive disease in 12.5%
(n = 1).The estimated 6 month local progression-free sur-
vival was 57.0%, shown in Figure 1. Median survival was
6.6 months, and the estimated 6 month overall survival was
57.8%, shown in Figure 2.
Treatment was extremely well tolerated, with only 1
case of Grade 3 toxicity, consisting of diarrhea in a pa-
tient who was being treated to the peritoneum. There
were no grade 4 or 5 toxicities. Importantly, there were
no Grade ≥3 toxicities seen in patients that were concur-
rently treated with tyrosine kinase inhibitors. Only one
patient experienced persistent dysgeusia after receiving
800 cGy × 3 fractions to the cervical spine. All other tox-
icities eventually resolved.
A summary of the patient cohort, tumor characteris-
tics, treatment indications and characteristics, outcomes,
and toxicities is listed in Table 1.Discussion
In our retrospective study, the use of radiation therapy





Figure 1 Local progression free survival. Kaplan-Meier survival curve for
of 57.0%.in a cohort of heavily pretreated patients with symptom-
atic GISTs.
Although a rare tumor, GIST incidence is increasing [2].
The cell of origin is thought to be the intestinal pacemaker
cells of Cajal. Tumors can arise in any location along the
gastrointestinal tract but are most commonly confined to
the stomach and small intestine. The primary therapy for
limited resectable disease is surgical resection. However,
recurrence is common, and the 5-year disease-free sur-
vival is only 45% after surgery alone [3].
Historically, GISTs have been very poorly responsive to
traditional cytotoxic chemotherapeutic agents. The discov-
ery that over 90% of GISTs harbor a mutation in one of
two tyrosine kinases (KIT and platelet-derived growth fac-
tor receptor, alpha polypeptide [PDGFR-a]) led to the
widespread use of biologically targeted agents for relapsed
or unresectable disease. Imatinib, a selective inhibitor of
the KIT protein tyrosine kinase that was developed to
treat chronic myelocytic leukemia, was shown to markedly
improve relapse-free survival in GIST patients [4-8] and
has since emerged as the primary treatment modality for
patients that have unresectable or metastatic disease [21].
Results of a recent ACOSOG Phase II trial also support
the use of imatinib in the adjuvant setting for high-risk pa-
tients [22] by demonstrating improved overall survival
compared with historical controls.
Unfortunately, the development of imatinib resistance
has become a problem among patients that experience an
initial response. Options for the management of resistant
disease include dose escalation of imatinib, or switching to
other tyrosine kinase inhibitors, which have shown activity
in imatinib-resistant disease [23-25]. However, prognosis (months)
local progression free survival showing estimated 6-month LPFS
Figure 2 Overall survival. Kaplan-Meier survival curve for overall survival showing median survival: 6.6 months and estimated 6 month overall
survival of 57.8%.
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within the abdomen or at distant sites often causes signifi-
cant pain and debilitation among a population with a lim-
ited lifespan.
For selected patients with focally progressive disease,
local therapies such as limited surgical resection [26-29],
radiofrequency ablation [30,31], and chemoembolization
[32] can provide palliation and durable freedom from
progression. Despite clear evidence of benefit from local-
ized therapies, radiation is rarely used in the manage-
ment of GISTs for either primary or salvage therapy.
There appear to be multiple reasons driving this omission.
First is the conventional consideration of GISTs as “radio-
resistant” tumors, perhaps due to their histological relation
to soft-tissue sarcomas, which have a relatively slow clin-
ical responsiveness to radiation therapy [33] Secondly,
retrospective case series showing a lack of benefit from ra-
diation therapy in the adjuvant setting after surgical resec-
tion of GISTs has further reduced enthusiasm for the use
of this modality [34,35]. Thirdly, the location of tumors
within the abdomen has also limited the ability to deliver
high doses of radiation therapy using conventional tech-
niques, due to the radiosensitivity of surrounding organs.
Finally, physicians may be hesitant to temporarily discon-
tinue TKI therapy to administer a course of palliative radi-
ation due to concerns of disease progression at other sites.
While simultaneous administration is an option, the in-
creased risk of high-grade dermatologic and mucosal tox-
icity when other TKIs (targeted against the epidermal
growth factor receptor) are used with radiation therapy[36] often deters physicians from recommending concur-
rent treatment.
Recently, new insights into the vast genetic and mo-
lecular heterogeneity of sarcomas, coupled with modern
organ-sparing radiation techniques, have challenged the
assumptions about radiation therapy in the management
of this disease. Several case reports throughout the lit-
erature have shown significant clinical and radiographic
responses with the use of radiation therapy, with the
ability to maintain long-term disease control and palliate
bone and visceral metastases in certain cases [9-20]. How-
ever, these studies are limited by small patient numbers
and the inherent selection and publication biases of single
patient reports. In the current study, all patients that were
treated consecutively at a single institution were included,
making for a more robust analysis, and representing the
largest report to date. Results from the current study cor-
roborate previous case reports, as radiation therapy was
shown to be highly effective in achieving at least partial
palliation in the majority of symptomatic patients. An ini-
tial radiographic response was seen in over a third of tu-
mors with adequate follow-up imaging. Toxicities were
largely related to the site being treated, were generally
mild, and the majority resolved shortly after treatment. In
regard to TKI-related toxicity, there were nine tumors that
were treated with concurrent tyrosine kinase inhibitor
therapy. Among these patients, there were no Grade ≥3
toxicities and no dermatologic toxicities, consistent with
previous phase I and II trials demonstrating the safety of
concurrent TKI therapy (albeit at a reduced daily dose)
Table 1 Patient, tumor, and treatment characteristics
Age Sex Tumor location Tumor
size (SPD)






Toxicity Grade Status at
last follow-up
56 F Left flank 50.95 Progression on imatinib Left flank pain 300 × 10 Y SD Partial Esophagitis 2 A
Left posterior
thorax
12.22 Progression on imatinib Left back pain 900 × 3 Y PR Partial None 0
T12-L1 vertebral
bodies
1.2 Progression on imatinib Left back pain 500 × 5 Y PR Partial None 0
41 M L3-L5 vertebral
bodies
120 Progression after multiple
surgical resections and
systemic chemotherapy
Decreased caliber of stools,
right hydronephrosis, groin
pain, abdominal pain, and
left leg edema
180 × 25 N PD Partial None 0 D
67 M Abdominal wall 45.92 Progression on nilotinib Abdominal pain 300 × 8 Y N/A None Fatigue 2 D
86 M Abdomen 94 Progression on Phase I
experimental targeted agents
Melena, hematemesis 300 × 10 N SD Complete Nausea, fatigue 1,1 A
73 M L3-S3 vertebral
bodies
N/A Development of pain while
on active surveillance
Left buttock and leg pain 300 × 9 N N/A Complete None 0 D
74 M T11 vertebral
body
4.14 Development of epidural
disease while on sunitinib
None 900 × 3 N PR N/A None 0 D
57 F Liver, anterior
abdominal wall




600 × 5 Y PR Complete None 0 D
C3-C4 vertebral
bodies
4.44 Progression on sorafenib Neck pain, numbness of
left shoulder and arm
800 × 3 Y SD Partial Dysgeusia 1
C2 vertebral
body
N/A Progression on nilotinib
and sirolimus
None 600 × 5 Y N/A N/A None 0




2400 × 1 N SD Partial Chest wall pain 1 D
69 F Right ilium and
L3 vertebral body
N/A Progression of symptoms
and inability to tolerate
systemic therapy
Low back pain, left sciatica,
right leg weakness
300 × 10 N SD Partial Diarrhea 2 D
74 F Peritoneum 142.3 Progression on Sorafenib Radiographic partial bowel
obstruction, nausea,
dyspepsia, constipation
300 × 10 N PR Partial Nausea, diarrhea 1,3 D
69 F Foramen
magnum to C2
N/A Progression on pazopanib Severe neck pain radiating
to occipital scalp and jaw
300 × 10 N N/A Complete None 0 D
T12 vertebral
body to sacrum
N/A Inability to tolerated
Phase I experimental
targeted therapy
Right buttock and sacral
discomfort
300 × 5 N N/A Partial None 0

















Table 1 Patient, tumor, and treatment characteristics (Continued)









None 300 × 10 N SD N/A None 0
58 M Left abdominal
mass




300 × 10 N SD Complete None 0 D
45 F L2-L3 vertebral
bodies
8.94 Development of painful
symptoms while on imatinib
Lumbar pain
exacerbated by sitting
2400 × 1 Y PR Complete None 0 D
64 M Pelvis 118.3 Attempt for presurgical
cytoreduction while
on sunitinib
None 200 × 25 Y SD N/A Diarrhea, urinary freq/
urgency, fatigue
1, 1, 1 A
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sults of the current study suggest that, for those patients
that are benefitting from TKI therapy at some sites of dis-
ease but progressing at others, concurrent radiation ther-
apy can be safe and effective in helping to control
symptoms of pain, weakness, and obstruction. Collectively,
these results indicate that radiation therapy can provide
both objective responses and symptomatic relief without
detracting dramatically from quality of life, and should be
considered in the multidisciplinary care of patients with
locally advanced or metastatic GISTs.
Our study is limited by its retrospective design. Be-
cause the follow-up schedule of the cohort was hetero-
geneous, conclusions regarding radiographic response
and toxicity are limited. Further, the non-uniformity of
the radiation doses makes it difficult to analyze dose re-
sponse and effectiveness of certain dose levels. Finally,
the follow-up for the cohort is short, reflecting the poor
prognosis of these advanced-stage, heavily pretreated pa-
tients. Despite these limitations, the findings remain hy-
pothesis generating and give important insights into a
treatment modality that appears to be safe and effective
in the management of patients with metastatic or locally
advanced GISTs.
Conclusions
This study represents the largest report of patients with
locally advanced and metastatic GISTs treated with radi-
ation therapy. Radiation was largely effective at achieving
palliation for symptomatic tumors, and radiographic re-
sponse is possible in some patients, providing evidence
that GIST is not universally radioresistant. Toxicities were
mild, and concurrent use of TKI therapy did not portend
an increased risk of side effects. Further study to establish
the role of radiation therapy in the management of gastro-
intestinal stromal tumors is needed and supported by the
findings of this report.
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